Seizert Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$44.3M Sell
729,793
-28,324
-4% -$1.65M 2.04% 20
2025
Q4
$40.9M Buy
758,117
+38,725
+5% +$1.86M 1.73% 27
2025
Q3
$32.4M Buy
719,392
+6,604
+0.9% +$308K 1.41% 32
2025
Q2
$33M Buy
712,788
+9,167
+1% +$450K 1.45% 34
2025
Q1
$42.9M Sell
703,621
-1,114
-0.2% -$64.9K 1.97% 21
2024
Q4
$39.9M Sell
704,735
-12,519
-2% -$699K 1.8% 24
2024
Q3
$37.1M Buy
717,254
+109,849
+18% +$5.15M 1.68% 25
2024
Q2
$25.2M Sell
607,405
-35,528
-6% -$1.59M 1.25% 33
2024
Q1
$34.9M Buy
642,933
+141,533
+28% +$7.21M 1.61% 28
2023
Q4
$25.7M Sell
501,400
-19,102
-4% -$1M 1.3% 34
2023
Q3
$30.2M Buy
520,502
+8,462
+2% +$518K 1.6% 26
2023
Q2
$32.7M Buy
512,040
+78,308
+18% +$5.25M 1.76% 23
2023
Q1
$30.1M Buy
433,732
+34,458
+9% +$2.43M 1.65% 24
2022
Q4
$28.7M Sell
399,274
-23,688
-6% -$1.79M 1.53% 24
2022
Q3
$30.1M Buy
422,962
+950
+0.2% +$68.9K 1.7% 23
2022
Q2
$32.5M Sell
422,012
-9,363
-2% -$713K 1.72% 22
2022
Q1
$31.5M Sell
431,375
-4,664
-1% -$313K 1.45% 29
2021
Q4
$27.2M Buy
436,039
+364,645
+511% +$21.4M 1.22% 34
2021
Q3
$4.22M Buy
71,394
+35,240
+97% +$2.32M 0.19% 81
2021
Q2
$2.42M Buy
36,154
+1,579
+5% +$103K 0.12% 108
2021
Q1
$2.18M Sell
34,575
-13,528
-28% -$842K 0.11% 111
2020
Q4
$2.98M Buy
48,103
+1,483
+3% +$91.2K 0.17% 70
2020
Q3
$2.81M Buy
46,620
+9,444
+25% +$568K 0.18% 68
2020
Q2
$2.19M Buy
37,176
+20,442
+122% +$1.22M 0.15% 71
2020
Q1
$933K Sell
16,734
-13,752
-45% -$841K 0.07% 109
2019
Q4
$1.96M Buy
30,486
+24,312
+394% +$1.39M 0.1% 93
2019
Q3
$313K Buy
6,174
+105
+2% +$4.93K 0.02% 176
2019
Q2
$275K Hold
6,069
0.01% 188
2019
Q1
$290K Hold
6,069
0.01% 197
2018
Q4
$315K Buy
6,069
+224
+4% +$12K 0.01% 180
2018
Q3
$363K Hold
5,845
0.01% 177
2018
Q2
$370K Hold
5,845
0.01% 181
2018
Q1
$370K Hold
5,845
0.01% 181
2017
Q4
$358K Buy
5,845
+1,000
+21% +$62.5K 0.01% 166
2017
Q3
$309K Sell
4,845
-4,000
-45% -$234K 0.01% 162
2017
Q2
$493K Sell
8,845
-860
-9% -$46.8K 0.02% 157
2017
Q1
$528K Hold
9,705
0.02% 161
2016
Q4
$567K Sell
9,705
-24,884
-72% -$1.36M 0.02% 162
2016
Q3
$1.86M Sell
34,589
-1,485
-4% -$95.4K 0.07% 119
2016
Q2
$2.65M Hold
36,074
0.1% 108
2016
Q1
$2.3M Sell
36,074
-90
-0.2% -$5.68K 0.08% 124
2015
Q4
$2.49M Hold
36,164
0.08% 131
2015
Q3
$2.14M Sell
36,164
-539
-1% -$34.2K 0.06% 132
2015
Q2
$2.44M Hold
36,703
0.06% 134
2015
Q1
$2.37M Sell
36,703
-1,140
-3% -$71.4K 0.06% 136
2014
Q4
$2.23M Sell
37,843
-3,803
-9% -$214K 0.05% 142
2014
Q3
$2.13M Sell
41,646
-885
-2% -$44.2K 0.04% 135
2014
Q2
$2.06M Hold
42,531
0.04% 137
2014
Q1
$2.21M Sell
42,531
-357
-0.8% -$19K 0.05% 85
2013
Q4
$2.28M Sell
42,888
-1,035
-2% -$52.7K 0.05% 78
2013
Q3
$2.03M Sell
43,923
-21,308
-33% -$935K 0.06% 78
2013
Q2
$2.92M Buy
+65,231
New +$2.83M 0.08% 71

Other funds holding BMY

Seizert Capital Partners's BMY Position: Q1 2026 in Review

Seizert Capital Partners reduced its Bristol-Myers Squibb (BMY) stake by 3.7% in Q1 2026, selling an estimated $1.65M and leaving 729,793 shares worth $44.3M. The position accounts for 2.04% of the portfolio, ranked #20.

Seizert Capital Partners first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Seizert Capital Partners held 729,793 shares of Bristol-Myers Squibb worth $44.3M as of Q1 2026.
  • Seizert Capital Partners sold 28,324 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.65M.
  • Bristol-Myers Squibb made up 2.04% of Seizert Capital Partners's portfolio in Q1 2026, its #20 holding.
  • Seizert Capital Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Seizert Capital Partners's 13F filing for Q1 2026, filed 7 May 2026.